Capsulution is Starting In-vivo Tests at Charité

Innovative Formulation of a Hormone Compound for Tumor Therapy

Berlin, (PresseBox) - The nanotechnology company Capsulution NanoScience AG (Berlin, Germany) has begun with pre-clinical in-vivo tests of innovative formulations of a hormone compound for tumor therapy. In collaboration with the “Forschungseinrichtung für Experimentelle Medizin” (FEM) at the Charité in Berlin, these tests investigate new kinds of depot formulations, which were developed on the basis of Capsulution’s technology platform in cooperation with an unnamed American company. By demonstrating this new kind of depot formulations Capsulution makes another important step establishing its patented technology in the field of pharmaceutical development. At the same time, the results of already generated in-vitro tests have served as the foundation for a contract development of yet another innovative hormone formulation.

Dr. Volker Fehring, Project Director at Capsulution, comments, “The in-vivo studies allow the efficient investigation of these new kinds of depot formulations on the pharmacokinetic, pharmacodynamic and histological levels. In combination with appropriate bioequivalence tests, Capsulution will get a deeper insight into the complex release and effective mechanisms and thus make it possible to fine-tune these depot formulations in a targeted manner.”

Upon successful conclusion of the tests, Capsulution and its partner are planning to further develop the product as fast as possible. Few contingency risks are expected on the way to regulatory approval of the finished formulations on the market. In contrast to the development of new chemical entities (NCE), the development of these formulations are based on active and excipient agents that have already been approved.

Capsulution Pharma AG

Capsulution NanoScience AG is a leading nanotechnology company focusing on the development of tailor-made drug delivery systems and other innovative life science products based on tunable nano-sized capsules. The company implements its worldwide-patented LBL Technology®. Based on their minute size, their functionality and their highly reproducible production process, the tunable capsules can be used in a multitude of different applications. Accordingly, the precision-sized capsules can be made to function in a manner suited to the intended application, and can be given biochemical, electrical, optical and magnetic properties tailored to the individual customer. In order to meet customers’ needs for complete product solutions, Capsulution designated EBARA Corp. as the preferred developer, manufacturer and distributor for automated LBL units. In 2005, the renowned growth consultants Frost & Sullivan awarded the year’s “Product Differentiation Innovation Award” in the global nanobiotechnology market to Capsulution NanoScience AG, Berlin. The company received the award for the innovative and diverse use of their proprietary nanobiotechnology product platform, which can be implemented in various life sciences applications.

Diese Pressemitteilungen könnten Sie auch interessieren

News abonnieren

Mit dem Aboservice der PresseBox, erhalten Sie tagesaktuell und zu einer gewünschten Zeit, relevante Presseinformationen aus Themengebieten, die für Sie interessant sind. Für die Zusendung der gewünschten Pressemeldungen, geben Sie bitte Ihre E-Mail-Adresse ein.

Es ist ein Fehler aufgetreten!

Vielen Dank! Sie erhalten in Kürze eine Bestätigungsemail.

Ich möchte die kostenlose Pressemail abonnieren und habe die Bedingungen hierzu gelesen und akzeptiert.